Last reviewed · How we verify
NCT03699956: REPLATINUM
RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer
Phase 3 trial testing RRx-001 + eLOOP Device in Carcinoma, Small Cell Lung in 18 participants. Terminated before completion.
11 August 2022
Quick facts
| Lead sponsor | EpicentRx, Inc. |
|---|---|
| Phase | Phase 3 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 18 |
| Start date | 24 December 2018 |
| Primary completion | 11 August 2022 |
| Estimated completion | 1 March 2024 |
| Sites | 18 locations across United States |
Drugs / interventions tested
- RRx-001 + eLOOP Device — full drug profile →
- Cisplatin/carboplatin plus etoposide — full drug profile →
Conditions studied
- Carcinoma, Small Cell Lung — all drugs for Carcinoma, Small Cell Lung →
Sponsor
EpicentRx, Inc. — full company profile →
Who can join
Adults 18 to 79, any sex, with Carcinoma, Small Cell Lung. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This Phase 3 study aims to find out whether RRx-001 + platinum chemotherapy is more effective than platinum chemotherapy alone in 3rd line or beyond small cell cancer.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications.
Ju HQ, Lin JF, Tian T, Xie D, et al · · 2020 · cited 365× · PMID 33028807 · DOI 10.1038/s41392-020-00326-0 -
The Role of Macrophages in Cancer Development and Therapy.
Cendrowicz E, Sas Z, Bremer E, Rygiel TP. · · 2021 · cited 246× · PMID 33919517 · DOI 10.3390/cancers13081946 -
Emerging phagocytosis checkpoints in cancer immunotherapy.
Liu Y, Liu Y, Wang Y, Yang Y, et al · · 2023 · cited 186× · PMID 36882399 · DOI 10.1038/s41392-023-01365-z -
Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed.
Qu T, Li B, Wang Y. · · 2022 · cited 66× · PMID 35418166 · DOI 10.1186/s40364-022-00373-5 -
Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity.
Archilla-Ortega A, Domuro C, Martin-Liberal J, Muñoz P. · · 2022 · cited 61× · PMID 35164813 · DOI 10.1186/s13046-022-02264-x -
Targeting the NLRP3 inflammasome for inflammatory disease therapy.
Cabral JE, Wu A, Zhou H, Pham MA, et al · · 2025 · cited 57× · PMID 40374417 · DOI 10.1016/j.tips.2025.04.007 -
REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer.
Oronsky B, Reid TR, Larson C, Caroen S, et al · · 2019 · cited 47× · PMID 31509028 · DOI 10.2217/fon-2019-0317 -
A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC).
Oronsky B, Abrouk N, Caroen S, Lybeck M, et al · · 2022 · cited 46× · PMID 35912017 · DOI 10.7150/jca.75622
Verify or expand the search:
- PubMed search for NCT03699956
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of RRx-001 + eLOOP Device
Trials testing the same drug.
- NCT05566041 — A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in S · Phase 3 · active not recruiting
Other recruiting trials for Carcinoma, Small Cell Lung
Currently open trials in the same condition.
- NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
- NCT07242547 — Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients · Phase 2 · recruiting
- NCT05566041 — A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in S · Phase 3 · active not recruiting
Other EpicentRx, Inc. trials
Trials by the same sponsor.
- NCT05966194 — RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer · Phase 2 · recruiting
- NCT04525014 — RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and · Phase 1 · terminated
- NCT05566041 — A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in S · Phase 3 · active not recruiting
- NCT04673942 — A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors · Phase 2 · recruiting
- NCT03515538 — Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatme · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03699956 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by EpicentRx, Inc.
- Last refreshed: 26 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03699956.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing